Skip to main content

Advertisement

SpringerLink
Log in

Surgical Management of Pancreatic Neoplasms: What’s New?

  • Pancreas and Biliary Tract (O Haluszka, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Pancreatic cancer is the fourth leading cause of cancer deaths in the USA. Although some patients will present with premalignant pancreatic lesions (i.e., intraductal papillary mucinous neoplasms) or localized tumors amenable to curative resection, the majority of patients will unfortunately present with technically unresectable or metastatic disease. This review of the recent medical literature will discuss the optimal work-up and management of premalignant pancreatic lesions and the surgical management of localized, borderline resectable, and locally advanced (i.e., unresectable) pancreatic tumors. It will focus on new criteria used to define surgical “resectability,” the significance and clinical impact of surgical margins, the role of multimodality therapy in the management of patients with borderline resectable or locally advanced tumors, the role of surgery for local or distant recurrence, and minimally invasive surgical approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1–7.

    Article  CAS  PubMed  Google Scholar 

  3. Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg. 1984;199:418–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatol Off J Int Assoc Pancreatol. 2006;6:17–32.

    Article  Google Scholar 

  5. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatol Off J Int Assoc Pancreatol. 2012;12:183–97. A summary of recent international consensus guidelines for the management of IPMNs and mucinous cystic neoplasms of the pancreas.

    Article  Google Scholar 

  6. Fritz S, Klauss M, Bergmann F, et al. Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg. 2012;256:313–20. A recent retrospective review from the University of Heidelberg which highlights the fact that all "Sendai" negative, BD IPMNS are indeed not benign, and that serum CEA and CA 19–9 may be of value in differentiating benign from malignant BD IPMNs.

    Article  PubMed  Google Scholar 

  7. Wong J, Weber J, Centeno BA, et al. High-grade dysplasia and adenocarcinoma are frequent in side-branch intraductal papillary mucinous neoplasm measuring less than 3 cm on endoscopic ultrasound. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2013;17:78–84. discussion p −5.

    Article  Google Scholar 

  8. Hirono S, Tani M, Kawai M, et al. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2012;255:517–22.

    Article  PubMed  Google Scholar 

  9. He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013;216:657–65. discussion 65–7. A retrospective review from the Johns Hopkins Medical Institutions which demonstrates that a significant proportion of patients status post complete resection of benign IPMNs will develop new IPMNs (and in some cases, invasive pancreatic cancers) at 1, 5, and 10 years after surgery.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2000;4:567–79.

    Article  CAS  Google Scholar 

  11. Konstantinidis IT, Warshaw AL, Allen JN, et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann Surg. 2013;257:731–6.

    Article  PubMed  Google Scholar 

  12. Kimbrough CW, St Hill CR, Martin RC, McMasters KM, Scoggins CR. Tumor-positive resection margins reflect an aggressive tumor biology in pancreatic cancer. J Surg Oncol. 2013;107:602–7. A retrospective review from the University of Louisville which suggests that R1 resections are not simply reflections of surgical technique, but also of biological aggressiveness (thus supporting the use of adjuvant multimodal therapy in these patients).

    Article  PubMed  Google Scholar 

  13. NCC clinical practice guidelines in oncology: pancreatic adenocarcinoma, version 1.2014. (Accessed 3/25/14, at http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.) An excellent summary of the evidence supporting current recommendations regarding the work-up, staging, multimodal management, and follow-up of patients with pancreatic adenocarcinoma.

  14. Kang CM, Chung YE, Park JY, et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012;16:509–17.

    Article  Google Scholar 

  15. Katz MH, Wang H, Balachandran A, et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012;16:68–78. discussion −9. A retrospective series from the University of Texas M.D. Anderson Cancer Center which suggests that neoadjuvant chemoradiation may optimize (retroperitoneal/SMA) margins and decrease local recurrence rates following pancreatectomy for localized pancreatic cancer.

    Article  Google Scholar 

  16. Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS. Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB Off J Int Hepato Pancreat Biliary Assoc. 2014;16:34–9.

    Article  Google Scholar 

  17. Papalezova KT, Tyler DS, Blazer 3rd DG, et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol. 2012;106:111–8. A retrospective series from Duke University which suggests that preoperative therapy may allow for better patient selection (and may result in better long-term outcomes) in patients with localized pancreatic cancer.

    Article  PubMed  Google Scholar 

  18. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148:362–75.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Zhao Q, Rashid A, Gong Y, et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012;16:29–37.

    Article  CAS  PubMed  Google Scholar 

  20. Arvold ND, Ryan DP, Niemierko A, et al. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2012;118:3026–35.

    Article  PubMed  Google Scholar 

  21. Esnaola NF, Chaudhary UB, O’Brien P, et al. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;88:837–44. A phase II clinical trial from the Medical University of South Carolina which suggests that induction combination chemotherapy, selective chemoradiation, and aggressive surgical resection is well tolerated and results in favorable long-term outcomes in patients with borderline resectable or unresectable locally advanced pancreatic cancer.

    Article  CAS  PubMed  Google Scholar 

  22. Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749–56.

    Article  PubMed  Google Scholar 

  23. Strobel O, Berens V, Hinz U, et al. Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery. 2012;152:S33–42.

    Article  PubMed  Google Scholar 

  24. Yamamoto Y, Sakamoto Y, Ban D, et al. Is celiac axis resection justified for T4 pancreatic body cancer? Surgery. 2012;151:61–9. This retrospective series from the National Cancer Center Central Hospital in Tokyo highlights the fact that en bloc, celiac axis resection for T4 pancreatic body cancer is associated with high rates of morbidity and poor long-term outcomes, even in highly selected cases performed at a high volume center.

    Article  PubMed  Google Scholar 

  25. Baumgartner JM, Krasinskas A, Daouadi M, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic adenocarcinoma following neoadjuvant therapy. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012;16:1152–9.

    Article  Google Scholar 

  26. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836–47.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Strobel O, Hartwig W, Hackert T, et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol. 2013;20:964–72.

    Article  PubMed  Google Scholar 

  28. Thomas RM, Truty MJ, Nogueras-Gonzalez GM, et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012;16:1696–704.

    Article  Google Scholar 

  29. Baker MS, Sherman KL, Stocker S, et al. Defining quality for distal pancreatectomy: does the laparoscopic approach protect patients from poor quality outcomes? J Gastrointest Surg Off J Soc Surg Aliment Tract. 2013;17:273–80.

    Article  Google Scholar 

  30. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Jean-Philippe A, Alexandre J, Christophe L, et al. Laparoscopic spleen-preserving distal pancreatectomy: splenic vessel preservation compared with the Warshaw technique. JAMA Surg. 2013;148:246–52.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Dr. Karachristos and Dr. Esnaola have no conflicts of interest to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, Temple University School of Medicine, 3401 N. Broad Street, Suite 330 (NFE) and 640 (AK), Philadelphia, PA, 19140, USA

    Andreas Karachristos & Nestor F. Esnaola

  2. Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA

    Andreas Karachristos & Nestor F. Esnaola

Authors
  1. Andreas Karachristos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nestor F. Esnaola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nestor F. Esnaola.

Additional information

This article is part of the Topical Collection on Pancreas and Biliary Tract

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karachristos, A., Esnaola, N.F. Surgical Management of Pancreatic Neoplasms: What’s New?. Curr Gastroenterol Rep 16, 397 (2014). https://doi.org/10.1007/s11894-014-0397-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-014-0397-x

Keywords

Search

Navigation